Pharma

To truly bring an end to the Covid-19 pandemic which has ravaged the globe, the Biden administration must embrace a strategy of vaccine equity.

The Covid-19 threat will not simply go away—especially when addressed with half measures. The administration must use its authority under the Defense Production Act much more wisely and aggressively.

Dr. Robert Califf appears to be the clearest front-runner for the (somehow) still open position of commissioner of the Food and Drug Administration. After floating his name in the press a few weeks ago, President Biden recently met with Califf in private. Such meetings tend to be the final step before a nominee is announced.

There’s just one problem: Califf is a longtime political consultant to Big Pharma and, more recently, to Big Tech. In fact, he’s so tied to those industries that he once earned the ire of a certain crucial senator from West Virginia.

Califf coordinates lobbying for major corporations — in his case, for Big Tech giants eager to get into the medical sector (and get into patients’ medical data.)

When United States Trade Representative Katherine Tai announced this past May that the U.S. would support the TRIPS waiver on COVID-19 vaccines at the World Trade Organization (WTO), we at the Revolving Door Project celebrated the administration’s decision as “a transformative, hopeful event.” The waiver proposal calls on the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council to suspend intellectual-property protections on COVID-19 therapeutics, diagnostics, and vaccines to ensure materials necessary for combating the pandemic are “available promptly, in sufficient quantities and at affordable price to meet global demand.”

Personnel vacancies and Big Pharma allies in the Biden administration threaten a landmark executive order on competition.

Fowler, a former Johnson & Johnson executive, is the latest Biden hire to spin through Pharma’s revolving door.

In 2019, Gallup found that the pharmaceutical industry was “the most poorly regarded industry in Americans’ eyes,” and rightfully so. Pharmaceutical companies often set drug prices exorbitantly high, including life-saving drugs which patients literally cannot go without, such as insulin. This includes older drugs that are cheaper to produce — such as epinephrine (emergency medication used to treat severe allergic reactions and asthma attacks). These firms achieve this by stifling competition at the consumer’s expense, jealously protecting their money-makers from the generics which the pharmaceutical system is supposed to develop after a patent expires.

If appointed, Turner would be a transparent and flagrant case study in the workings of the revolving door, which means he would be right in line with the IP orthodoxy PTO has upheld.

When choosing the next PTO director, the Biden administration should rule out those who have a history of prioritizing profits and corporate interests over public health and safety. One such individual is Kevin Rhodes, an ally of Big Pharma who has vigorously defended efforts to keep drug prices high. His current employer, 3M, has abused its monopoly on the military earplug market to sell overpriced and faulty products to veterans. This should be immediately disqualifying for any future PTO director. Here are a few of the most alarming aspects of Kevin Rhodes’s career:

The Biden administration is divided over whether to waive trade protections for Big Pharma—with Commerce Secretary Gina Raimondo as a key industry ally.